FDA Updates Menopause Hormone Therapy Warnings: What Women Need to Know

Sep 2

3 min read

For years, many women have been hesitant to consider menopausal hormone therapy (MHT) because of warnings about breast cancer, heart disease, blood clots, and dementia. Updated FDA labeling is helping create a more accurate and individualized conversation about hormone therapy.

At Egan Wellness & Med Spa, we believe women deserve current, evidence-based information about menopause and their treatment options.

What Changed With Menopause Hormone Therapy?

The FDA has removed certain longstanding boxed warnings from menopausal hormone therapy labeling, including warnings related to cardiovascular disease, thromboembolism, breast cancer, and probable dementia.

These warnings were heavily influenced by the Women’s Health Initiative (WHI). Importantly, the women in that study were, on average, about 63 years old and many were considerably farther from menopause than women who typically seek treatment for menopausal symptoms.

Today, we understand that the benefits and risks of hormone therapy can vary depending on age, timing, type of hormone, route of administration, dose, and individual health history.

The updated labeling supports a more individualized approach rather than assuming all hormone therapy carries the same risk.

What About Vaginal Estrogen?

Low-dose vaginal estrogen is commonly used for vaginal dryness, irritation, painful intercourse, and certain urinary symptoms associated with menopause.

Because low-dose vaginal estrogen generally results in minimal systemic absorption, its risk profile differs from systemic hormone therapy.

The updated labeling may help reduce unnecessary fear surrounding local estrogen treatment. However, women with a history of estrogen-sensitive breast cancer should still discuss treatment with their healthcare and oncology teams.

Is Systemic Estrogen Safe?

Systemic hormone therapy can be highly effective for appropriate women experiencing hot flashes, night sweats, sleep disruption, and other bothersome menopausal symptoms.

However, the FDA changes do not mean hormone therapy is risk-free or appropriate for everyone.

At Egan Wellness & Med Spa, we believe hormone therapy should be individualized based on your symptoms, age, time since menopause, medical history, cardiovascular risk, breast health, and personal goals.

The type and route of hormone therapy also matter. Oral and transdermal estrogen are not identical, and the choice may be important for certain women. For women with a uterus using systemic estrogen, progesterone is generally needed to protect the uterine lining.

Menopause Care Should Be Personalized

The FDA's updated labeling represents an important step toward a more nuanced understanding of menopause hormone therapy.

It does not mean every woman should take hormones. Instead, it emphasizes the importance of evaluating each woman individually and making treatment decisions based on current evidence.

At Egan Wellness & Med Spa, our goal is to help women understand their options and make informed decisions about their health.

If menopause symptoms are affecting your sleep, energy, mood, relationships, work, or quality of life, talk with a qualified healthcare professional about whether hormone therapy may be right for you.

Frequently Asked Questions

Is hormone replacement therapy safe after menopause?For appropriately selected women, hormone therapy can provide significant benefits. Safety depends on factors including age, timing, type of therapy, route, and individual medical history.

Is vaginal estrogen safer than systemic estrogen?Low-dose vaginal estrogen generally has minimal systemic absorption and is used primarily for genitourinary symptoms. Individual circumstances still need to be considered.

Does the FDA update mean hormone therapy is safe for everyone?No. The updated labeling does not eliminate individual risks or make hormone therapy appropriate for every woman. Personalized medical evaluation remains essential.